From process transfer to GMP production: the story continued at INITS SMO with Alga Biologics!

Last July, we welcomed Alga Biologics on-site to officially launch our joint operations, starting with process transfer: https://lnkd.in/etfgfSH3

Today, we are proud to announce that Alga Biologics' team returned on-site last week to produce their first GMP batch of microalgae-derived therapeutic antibodies!

Christelle Fécourt and Manon Salvetti worked side by side with our experts: @Ludivine DEJOINT, Loïc PERILLEUX and Daniel Haugg.

This illustrates the essence of the INITS SMO model: the biotech keeps full ownership of its process and know-how, and produces its own batches in our GMP facilities, while INITS provides the complete support framework: quality assurance, quality control, project management, regulatory, supply.

Supporting a disruptive technology like Alga Biologics' microalgae biomanufacturing platform reach GMP production is a key milestone for their clinical development, and for the future of sustainable decarbonated biomanufacturing.

More than an innovative GMP production batch, this is the proof that the SMO model turns innovation into industrial reality.

Stay tuned, the journey to the clinic continues!